Why insurance often won’t cover branded GLP-1 — and what that means

The phrase “GLP-1 coverage” compresses a lot of complexity. Coverage in the US depends on which insurer you have, which formulary tier the specific drug sits on, the indication for which it is being prescribed, whether your employer chose to include obesity-specific medications, and whether the prescribing clinician is willing to invest the administrative time to push a prior authorization through. In 2026, the realistic picture for most adults seeking GLP-1 therapy for weight management is that branded products are difficult to get covered, and the difficulty is the context for everything else in this post. Compounded GLP-1 is compounded under section 503A of the FD&C Act; compounded GLP-1 is NOT FDA-approved as a finished product, and the access conversation matters in part because of how 503A is allowed to fill the gap.

How prior authorization actually works

Prior authorization (PA) is the process by which a pharmacy benefit manager (PBM) decides whether your insurer will pay for a medication before it is dispensed. For GLP-1 receptor agonists, common PA criteria include some combination of:

• BMI thresholds, often higher than the published indication — for example, BMI ≥ 35 rather than ≥ 30.
• Documented comorbidity (type 2 diabetes, sleep apnea, hypertension).
• A documented prior weight-loss attempt with a structured program, usually three to six months of medically supervised lifestyle intervention.
• Step therapy: failure on a less-expensive medication first (for example, an older anti-obesity agent).
• Renewal criteria: documented weight loss of a certain percentage within a set number of months, or coverage stops.

The clinician’s office submits a PA packet. The PBM reviews. Denials are common. Appeals are possible but time-consuming. Even when a PA is approved, the patient may face a copay tier that runs hundreds of dollars per month, depending on the plan.

Why employer plans often exclude weight-management coverage

The other big variable is what your employer chose to buy. Self-insured employers and the plans they sponsor make active decisions about whether to include anti-obesity medications as a covered benefit category. Many do not, and the most common stated reason is cost projection — if a significant fraction of the workforce became eligible and adherent, the projected annual pharmacy spend climbs sharply. In 2026, the majority of employer plans still exclude or significantly restrict anti-obesity medication coverage, and the patient ends up paying out of pocket regardless of clinical appropriateness.

Patients with diabetes-indicated coverage sometimes find a different door open: a GLP-1 prescribed for type 2 diabetes (e.g., a brand with a diabetes indication) may be covered, even if the same molecule prescribed for weight management would not be. That is a regulatory artifact, not a clinical insight. The molecule does the same thing either way.

The denial patterns patients see

The straightforward formulary exclusion

The plan’s formulary simply does not list the drug, or lists it as non-covered for the indication. There is no PA to file because there is no covered route at all. These denials are not appealable in any meaningful sense; the answer is “buy it yourself, change plans, or change drugs.”

The “almost qualifies” PA denial

The plan covers the drug for weight management, but the PA criteria require BMI 35 and the patient is BMI 33. Or step therapy requires a documented three-month trial of an older medication first. These denials can sometimes be appealed with additional documentation, but the time and effort fall on the patient and the prescribing clinician.

The copay shock

The PA is approved, but the drug sits on a specialty or non-preferred tier. The patient’s out-of-pocket monthly cost lands in a range that is functionally unsustainable. This is technically “covered” and statistically counted as such by the insurer, but it does not mean the medication is accessible.

Where compounded 503A care fits

The conditions under which 503A compounding of GLP-1 preparations is legally permitted are tied in part to the FDA’s drug shortage list and to the patient-specific prescription model. The access conversation matters because, for a meaningful slice of adults, the alternative to 503A care is no care, or a series of denials and appeals that take months while metabolic and behavioral momentum decays. A state-licensed 503A pharmacy preparing a patient-specific compound, under a valid prescription from a licensed clinician, exists in part to address that access gap.

That is not the same as saying compounded GLP-1 is a replacement for, or equivalent to, finished branded products. It is not. We are simply being honest about the role 503A plays in the current system: a regulated, patient-specific pathway that allows clinicians to treat eligible adults when the standard finished-product supply chain is restricted by cost, coverage, or shortage status.

What to actually do about your own coverage

A short, practical checklist before assuming you are stuck:

• Call the member services number on the back of your insurance card. Ask, by drug name, whether the specific GLP-1 is covered, on what tier, and for which indications.
• Ask whether prior authorization is required and request the PA criteria document in writing.
• If you have an HSA or FSA, find out whether out-of-pocket compounded medications are eligible for reimbursement under your plan.
• If your employer plan excludes anti-obesity medications, raise it with HR or benefits at the next plan year. Coverage policies do change.
• If you decide to pay out of pocket, compare total monthly cost — medication, clinician visits, support — across programs, not just headline numbers.

The honest summary

Most adults seeking GLP-1 therapy for weight management in 2026 are paying out of pocket somewhere — either for the medication directly, for the program around it, or both. The job of a responsible telehealth platform is to be clear about what you are buying, what the medication category is and is not, and what the clinical relationship looks like after the first month. That is the part the insurance conversation almost never covers. It is also the part that determines whether the money you spend turns into care.